reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
For many years, controversy has surrounded the use of involuntary treatment and use of the term "lack of insight" in describing patients. Internationally, mental health laws vary significantly but in many cases, involuntary psychiatric treatment is permitted when there is deemed to be a significant risk to the patient or others due to the patient's illness. Involuntary treatment refers to treatment that occurs based on a treating physician's recommendations, without requiring consent from the patient. Inpatient psychiatric wards may be secure (for those thought to have a particular risk of violence or self-harm) or unlocked/open. Some wards are mixed-sex whilst same-sex wards are increasingly favored to protect women inpatients. Once in the care of a hospital, people are assessed, monitored, and often given medication and care from a multidisciplinary team, which may include physicians, pharmacists, psychiatric nurse practitioners, psychiatric nurses, clinical psychologists, psychotherapists, psychiatric social workers, occupational therapists and social workers. If a person receiving treatment in a psychiatric hospital is assessed as at particular risk of harming themselves or others, they may be put on constant or intermittent one-to-one supervision and may be put in physical restraints or medicated. People on inpatient wards may be allowed leave for periods of time, either accompanied or on their own. In many developed countries there has been a massive reduction in psychiatric beds since the mid 20th century, with the growth of community care.
There is evidence suggesting corneal collagen cross-linking may be beneficial for patients with pellucid marginal degeneration. Research shows some promising results by combining collagen cross linking with photorefractive keratectomy, or with topography-guided transepithelial surface ablation.
=== Cancer === In a 2022 update of an earlier report, the United States Preventive Services Task Force recommended against the use of vitamin E supplements for the prevention of cardiovascular disease or cancer, concluding there was insufficient evidence to assess the balance of benefits and harms, yet also concluding with moderate certainty that there is no net benefit of supplementation. As for literature on different types of cancer, an inverse relationship between dietary vitamin E and kidney cancer and bladder cancer is seen in observational studies. A large clinical trial reported no difference in bladder cancer cases between treatment and placebo. An inverse relationship between dietary vitamin E and lung cancer was reported in observational studies, but a large clinical trial in male tobacco smokers reported no impact on lung cancer between treatment and placebo, and a trial which tracked people who chose to consume a vitamin E dietary supplement reported an increased risk of lung cancer for those consuming more than 215 mg/day. For prostate cancer, there are also conflicting results. A meta-analysis based on serum alpha-tocopherol content reported an inverse correlation in relative risk, but a second meta-analysis of observational studies reported no such relationship. A large clinical trial with male tobacco smokers and reported a 32% decrease in the incidence of prostate cancer, but the SELECT trial of selenium or vitamin E for prostate cancer enrolled men ages 55 or older and reported relative risk 17% higher for the vitamin group.
Anne Jamieson Hosie, Executive Officer, the Benefits Agency, Department of Social Security. Ralph John Howe, Gardener, Kettering General Hospital, Northamptonshire. For services to Health Care. Arthur William Howell, leading Firefighter, London Fire and Civil Defence Authority. For services to the Fire Service. Edna Emily Howes. For services to the Royal British Legion in Northamptonshire. Denis Arthur Huggons. For services to the London Gardens Society. Margaret Florence Hughes, Postwoman, Royal Mail. For services to the Post Office and to the community in Wollaston, Northamptonshire. Mildred Emily Hughes, Chief Clerk, Llangefni County Court, Lord Chancellor's Department. David Bain Hume, Director, Philomusica. For services to Music in Edinburgh. Dorothy Hunt. For services to the Sea Cadet Corps in Nottingham. Sarah Ruth Hunt. For services to Disabled Children in Northampton. Marion Hunter. For services to the Fire Service. John Malcolm Huntington. For services to Sports Journalism in Yorkshire. Margaret Isobel Hutcheon, Headteacher, Mosstowie Primary School, Morayshire. For services to Education. Helen Rosalind Hutchinson, Tourist Guide. For services to Tourism. Derek Cecil George Hynds, Senior Professional and Technology Officer, Ministry of Defence. Simon Louis Jackson. For services to Judo for Disabled People. Sydney Frederic Jacobs. For services to the community in Liverpool. Arjan Singh Jagdev. For services to the ethnic community in Merton, London. Mary James. For services to Farming and to Consumer Affairs. John Malcolm Jefkins. For political service.
=== Forms === Spironolactone is available in the form of tablets (25, 50, and 100 mg; brand name Aldactone, others) and suspensions (25 mg/5 mL; brand name Carospir) for oral administration. It had also been marketed in the form of 2 or 5% topical cream in Italy for the treatment of acne and hirsutism under the brand name Spiroderm, but this product is no longer available. The medication is also available in combination with other medications, such as hydrochlorothiazide (brand name Aldactazide, others). Spironolactone has poor water solubility, so only oral and topical formulations have been developed; other routes of administration such as intravenous injection are not used. The only antimineralocorticoid that is available as a solution for parenteral use is the related medication potassium canrenoate.
Sources: en.wikipedia.org
=== 24 April === Russian forces stopped an attack on the Black Sea Fleet base at Sevastopol. The Russian defence ministry said that "three unmanned high-speed boats" were destroyed. Ukraine did not comment on the attack.
The end point of translational research in medicine is the production of a promising new treatment that can be used clinically. Translational research is conceived due to the elongated time often taken to bring to bear discovered medical idea in practical terms in a health system. It is for these reasons that translational research is more effective in dedicated university science departments or isolated, dedicated research centers. Since 2009, the field has had specialized journals, the American Journal of Translational Research and Translational Research dedicated to translational research and its findings. Translational research in biomedicine is broken down into different stages. In a two-stage model, T1 research, refers to the "bench-to-bedside" enterprise of translating knowledge from the basic sciences into the development of new treatments and T2 research refers to translating the findings from clinical trials into everyday practice, although this model is actually referring to the 2 "roadblocks" T1 and T2. Waldman et al. propose a scheme going from T0 to T5. T0 is laboratory (before human) research. In T1-translation, new laboratory discoveries are first translated to human application, which includes phase I & II clinical trials. In T2-translation, candidate health applications progress through clinical development to engender the evidence base for integration into clinical practice guidelines. This includes phase III clinical trials. In T3-translation, dissemination into community practices happens.
The known active constituent of Salvia divinorum is a trans-neoclerodane diterpenoid known as salvinorin A (chemical formula C23H28O8). This compound is present in the dried plant at about 0.18%. Salvinorin A is not an alkaloid (meaning it does not contain a basic nitrogen), unlike most known opioid receptor ligands. Salvinorin A is the first documented diterpene hallucinogen. Similar to many psychoactive herbs, Salvia divinorum synthesizes and excretes its active constituent (salvinorin A) via trichomes, of the peltate-glandular morphology, located just beneath the cuticle (subcuticular) layer.
These drugs have been derived from NSAIDs. The cyclooxygenase enzyme inhibited by NSAIDs was discovered to have at least two different versions: COX-1 and COX-2. Research suggested most of the adverse effects of NSAdiated by blocking the COX-1 (constitutive) enzyme, with the analgesic effects being mediated by the COX-2 (inducible) enzyme. Thus, the COX-2 inhibitors were developed to inhibit only the COX-2 enzyme (traditional NSAIDs block both versions in general). These drugs (e.g., rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular. After widespread adoption of the COX-2 inhibitors, it was discovered that most of the drugs in this class increase the risk of cardiovascular events by 40% on average. This led to the withdrawal of rofecoxib and valdecoxib, and warnings on others. Etoricoxib seems relatively safe, with the risk of thrombotic events similar to that of non-coxib NSAID diclofenac.
{\displaystyle {\begin{aligned}\log K_{{\text{assoc}},1}&=\mathrm {p} K_{{\text{dissoc}},3}\\\log K_{{\text{assoc}},2}&=\mathrm {p} K_{{\text{dissoc}},2}\\\log K_{{\text{assoc}},3}&=\mathrm {p} K_{{\text{dissoc}},1}\end{aligned}}}
Sources: en.wikipedia.org
== Training == Proprioception is what allows someone to learn to walk in complete darkness without losing balance. During the learning of any new skill, sport, or art, it is usually necessary to become familiar with some proprioceptive tasks specific to that activity. Without the appropriate integration of proprioceptive input, an artist would not be able to brush paint onto a canvas without looking at the hand as it moved the brush over the canvas; it would be impossible to drive an automobile because a motorist would not be able to steer or use the pedals while looking at the road ahead; a person could not touch type or perform ballet; and people would not even be able to walk without watching where they put their feet. Oliver Sacks reported the case of a young woman who lost her proprioception due to a viral infection of her spinal cord. At first she could not move properly at all or even control her tone of voice (as voice modulation is primarily proprioceptive). Later she relearned by using her sight (watching her feet) and inner ear only for movement while using hearing to judge voice modulation. She eventually acquired a stiff and slow movement and nearly normal speech, which is believed to be the best possible in the absence of this sense. She could not judge effort involved in picking up objects and would grip them painfully to be sure she did not drop them.
Apples have also been infected to a limited extent. Besides its pathogenic interactions, P. digitatum has been implicated in naturally accelerating the ripening of green fruits, and causing epinastic responses in various plants such as potato, tomato, and sunflowers.
Most white Rhodesians felt that they were due independence following four decades of self-government, and that the British government was betraying them by withholding it. A stalemate developed between the British and Rhodesian prime ministers, Harold Wilson and Ian Smith respectively, between 1964 and 1965. The dispute largely surrounded the British condition that the terms for independence had to be acceptable "to the people of the country as a whole"; Smith contended that this was met, while the UK and African Nationalist Rhodesian leaders held that it was not. After Wilson proposed in late October 1965 that the UK might safeguard future black representation in the Rhodesian parliament by withdrawing some of the colonial government's devolved powers, then presented terms for an investigatory Royal Commission that the Rhodesians found unacceptable, Smith and his Cabinet declared independence. Calling this treasonous, the British colonial governor, Sir Humphrey Gibbs, formally dismissed Smith and his government, but they ignored him and appointed an "Officer Administering the Government" to take his place. While no country recognised the UDI, the Rhodesian High Court deemed the post-UDI government legal and de jure in 1968. The Smith administration initially professed continued loyalty to Queen Elizabeth II, but abandoned this in 1970 when it declared a republic in an unsuccessful attempt to win foreign recognition.
=== Pharmacodynamics === 2C-T-36 has a Ki of 0.35 nM at the serotonin 5-HT2A receptor, and an EC50Tooltip half-maximal effective concentration of 4.1 nM at the serotonin 5-HT2A receptor and 7.3 nM at the serotonin 5-HT2C receptor, compared to 88 nM at the serotonin 5-HT2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.